A technician works with genome samples at a lab of the biotech company in Beijing. Photo: Reuters A technician works with genome samples at a lab of the biotech company in Beijing. Photo: Reuters
A technician works with genome samples at a lab of the biotech company in Beijing. Photo: Reuters
Cancer

Top JPMorgan banker sees steady supply of Chinese health care IPOs, even amid valuation concerns

  • Chinese companies and investors raised US$18.3 billion from 77 new and secondary listings globally last year, according to Refinitiv
  • It is debatable whether record-high valuations can hold as investors chase a scarce supply of targets, says Fang Min of Warburg Pincus

Topic |   Cancer
A technician works with genome samples at a lab of the biotech company in Beijing. Photo: Reuters A technician works with genome samples at a lab of the biotech company in Beijing. Photo: Reuters
A technician works with genome samples at a lab of the biotech company in Beijing. Photo: Reuters
READ FULL ARTICLE